Search

Displaying results 7971 - 7980 of 10000 in total
  1. Drug

    MLN0415

    go.drugbank.com/drugs/DB05183
    Experimental

    MLN0415 is a novel, small molecule IKK2 inhibitor, discovered by Millennium scientists. … In preclinical studies, MLN0415 was shown to decrease NF-kB activation and down-regulate the expression of a number of inflammatory proteins.

  2. Drug

    Imgatuzumab

    go.drugbank.com/drugs/DB14884
    Investigational

    Imgatuzumab is under investigation in clinical trial NCT01326000 (A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With

  3. Drug

    Alobresib

    go.drugbank.com/drugs/DB14970
    Investigational

    Alobresib is under investigation in clinical trial NCT02607228 (Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants

  4. Drug

    Rocapuldencel-T

    go.drugbank.com/drugs/DB17588
    Investigational

    Rocapuldencel-T is an autologous dendritic cell immunotherapy that was investigated in NCT02662634 (A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer

  5. Drug

    AVXS-301

    go.drugbank.com/drugs/DB17943
    Experimental

    AVXS-301 consists of an adeno-associated virus serotype 9 (AAV9) designed to express the superoxide dismutase 1 (SOD1) gene.

  6. Drug

    beta-Naphthoflavone

    go.drugbank.com/drugs/DB06732
    Experimental

    It may be a chemopreventive agent. … β-Naphthoflavone, also known as 5,6-benzoflavone, is a potent agonist of the aryl hydrocarbon receptor and induces cytochromes P450 (CYPs) and uridine 5'-diphospho-glucuronosyltransferases (UGTs).

  7. Drug

    (+)-Mefloquine

    go.drugbank.com/drugs/DB05636
    Investigational

    (+)-Mefloquine was under investigation in clinical trial NCT00931697 (Study to Investigate the Safety, Tolerability and Pharmacokinetics of AD 452 [(+)-Mefloquine] Compared With Racemic Mefloquine) to

  8. Drug

    Canertinib

    go.drugbank.com/drugs/DB05424
    Investigational

    Canertinib treatment significantly affects tumour metabolism, proliferation and hypoxia as determined by PET. … Canertinib is a pan-erbB tyrosine kinase inhibitor which work against esophageal squamous cell carcinoma in vitro and in vivo.

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Mito-4509

    go.drugbank.com/drugs/DB05846
    Experimental

    Mito-4509 is a non-feminizing estrogen analog that could affect mitochondrial metabolic pathways.

  10. Drug

    UC-781

    go.drugbank.com/drugs/DB05871
    Investigational

    UC-781 is a thiocarboxanilide non-nucleoside reverse transcriptase inhibitor (NNRTI). It is a topical microbicide targeted against the AIDS virus.